Matches in SemOpenAlex for { <https://semopenalex.org/work/W2272296618> ?p ?o ?g. }
Showing items 1 to 38 of
38
with 100 items per page.
- W2272296618 endingPage "iv17" @default.
- W2272296618 startingPage "iv17" @default.
- W2272296618 abstract "ABSTRACT Therapies currently available for treatment of patients with metastatic renal cell carcinoma (mRCC) include those that target the VEGF pathway and the mTOR pathway. VEGF pathway inhibitors include the multi-targeted receptor tyrosine kinase inhibitors sunitinib, sorafenib, pazopanib, and axitinib (VEGFr-TKIs) and the monoclonal antibody bevacizumab. The mTOR inhibitors include everolimus and temsirolimus. The international clinical guidelines recommend sunitinib, pazopanib, and bevacizumab (plus interferon-a) as first-line therapies for patients with mRCC who have a good prognosis and temsirolimus for patients who have a poor prognosis. Recently reported results of the COMPARZ and PISCES studies demonstrated that patients favor pazopanib over sunitinib as first-line treatment for mRCC based on better general quality of life. Everolimus is recommended for treatment of patients who failed previous VEGFr-TKI therapy. Sorafenib, sunitinib, and pazopanib are recommended for cytokine-refractory patients and axitinib is recommended for treatment of patients who failed previous cytokine or VEGFr-TKI therapy. Approved treatments are not curative; median overall survival remains suboptimal and most patients with mRCC who are treated with VEGF-targeted agents or mTOR inhibitors will eventually develop resistance and subsequently experience disease progression. With the primary goal of optimizing the treatment of patients with mRCC, multiple agents targeting various pathways are currently in development. These include targeted immunotherapeutics as well as innovative drugs directed to novel targets that might be biologically relevant for this disease, like cMET, Tie2, ALK1/ENG, PI3K, Akt, mTORC1/2 inh. Looking to the future, it will be imperative, as well, to identify predictive biomarkers to further refine treatment options and to identify the optimal treatment for individual patients with mRCC. Disclosure: E. Calvo: Research funding from Novartis, Pfizer, GSK, Roche." @default.
- W2272296618 created "2016-06-24" @default.
- W2272296618 creator A5053069942 @default.
- W2272296618 date "2014-09-01" @default.
- W2272296618 modified "2023-09-26" @default.
- W2272296618 title "New Drugs and New Targets in Rcc" @default.
- W2272296618 doi "https://doi.org/10.1093/annonc/mdu299.4" @default.
- W2272296618 hasPublicationYear "2014" @default.
- W2272296618 type Work @default.
- W2272296618 sameAs 2272296618 @default.
- W2272296618 citedByCount "0" @default.
- W2272296618 crossrefType "journal-article" @default.
- W2272296618 hasAuthorship W2272296618A5053069942 @default.
- W2272296618 hasBestOaLocation W22722966181 @default.
- W2272296618 hasConcept C71924100 @default.
- W2272296618 hasConcept C98274493 @default.
- W2272296618 hasConceptScore W2272296618C71924100 @default.
- W2272296618 hasConceptScore W2272296618C98274493 @default.
- W2272296618 hasLocation W22722966181 @default.
- W2272296618 hasOpenAccess W2272296618 @default.
- W2272296618 hasPrimaryLocation W22722966181 @default.
- W2272296618 hasRelatedWork W1506200166 @default.
- W2272296618 hasRelatedWork W1995515455 @default.
- W2272296618 hasRelatedWork W2039318446 @default.
- W2272296618 hasRelatedWork W2048182022 @default.
- W2272296618 hasRelatedWork W2080531066 @default.
- W2272296618 hasRelatedWork W2604872355 @default.
- W2272296618 hasRelatedWork W2748952813 @default.
- W2272296618 hasRelatedWork W2899084033 @default.
- W2272296618 hasRelatedWork W3032375762 @default.
- W2272296618 hasRelatedWork W3108674512 @default.
- W2272296618 hasVolume "25" @default.
- W2272296618 isParatext "false" @default.
- W2272296618 isRetracted "false" @default.
- W2272296618 magId "2272296618" @default.
- W2272296618 workType "article" @default.